Diabetes Mellitus, Type I
Metabolic Diseases
1
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Allergy TherapeuticsUK - West Sussex
1 program1
Low Molecular Weight Sulfated DextranPhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Allergy TherapeuticsLow Molecular Weight Sulfated Dextran
GentiBioblood draw
Leadiant BiosciencesCarnitine
Clinical Trials (3)
Total enrollment: 250 patients across 3 trials
Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant
Start: Jul 2008Est. completion: Oct 2009
Phase 2Withdrawn
HLA Demographics Study in Adults With Type 1 Diabetes
Start: Jun 2025Est. completion: Jun 202650 patients
N/ARecruiting
Carnitine Levels and Carnitine Supplementation in Type I Diabetes
Start: Oct 2004Est. completion: Apr 2007200 patients
N/ACompleted
Related Jobs in Metabolic Diseases
Manager, Patient Safety and Pharmacovigilance Operations
Kailera Therapeutics
Waltham, Massachusetts
6h ago
Senior Medical Science Liaison - Obesity - Northern CA, Central CA, NV
Amgen
California - San Francisco, US
Yesterday
(Sr) Scientist Analytical Chemistry – Mass Spectrometry (Temporary role 3 years)
Johnson & Johnson
Beerse, Antwerp, Belgium
2d ago
Computational Chemist
Topos Bio
San Francisco Office
2d ago
Associate Director, Legal Operations & Contracts Management
Kailera Therapeutics
Massachusetts
4d ago
From $155K/yr
Diagnostics Value Consultant(Product Marketing) - Diabetes Care Portfolio
Roche
Taipei
5d ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 250 patients
3 companies competing in this space